A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma
/in Dendritic Cells, Glioblastoma, International Publications /von 2021-12-03 / Clin Cancer Res 2021 Dec;Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas
/in Glioblastoma, International Publications, Newcastle Disease Virus /von 2021-10-05 / Front Immunol 2021;12:721830Making a Cold Tumor Hot: The Role of Vaccines in the Treatment of Glioblastoma
/in Dendritic Cells, Glioblastoma, International Publications /von 2021-05-10 / Front Oncol 2021;11:672508Magnetic Hyperthermia as an adjuvant cancer therapy in combination with radiotherapy versus radiotherapy alone for recurrent/progressive glioblastoma: a systematic review
/in Glioblastoma, Hyperthermia, International Publications /von 2021-03-13 / J Neurooncol 2021 May;152(3):419-428DNA methylation based glioblastoma subclassification is related to tumoral T-cell infiltration and patient survival
/in Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2021-02-25 / Neuro Oncol 2021 02;23(2):240-250The oncolytic Newcastle disease virus as an effective immunotherapeutic strategy against glioblastoma
/in Glioblastoma, International Publications, Newcastle Disease Virus /von 2021-02-01 / Neurosurg Focus 2021 02;50(2):E8Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged
/in Dendritic Cells, Glioblastoma, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2020-12-24 / Cancers (Basel) 2020 Dec;13(1)Antitumor Activity of Curcumin in Glioblastoma
/in Curcuma, Glioblastoma, International Publications /von 2020-12-11 / Int J Mol Sci 2020 Dec;21(24)Hyperthermia treatment advances for brain tumors
/in Glioblastoma, Hyperthermia, International Publications /von 2020-07-01 / Int J Hyperthermia 2020 07;37(2):3-19
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Molecular Mechanisms of Anti-Neoplastic and Immune Stimulatory Properties of Oncolytic Newcastle Disease Virus
- Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
- A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma